Opinion
Video
Panelists discuss how patient-specific factors including age, comorbidities, genetic profile, and treatment goals guide the selection between doublet and triplet regimens in chronic lymphocytic leukemia (CLL), with considerations like Bruton tyrosine kinase inhibitor tolerability, desire for time-limited therapy, and high-risk features informing the choice between various BTK inhibitor–based combinations with venetoclax and obinutuzumab.
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Video content above is prompted by the following:
OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer
Bezuclastinib Plus Sunitinib Elicits Preliminary Activity, Is Safe in Pretreated GIST
Post-Chemotherapy ctDNA Status May Support Organ Preservation Decisions in Rectal Cancer
Adagrasib/Cetuximab Maintains Efficacy in KRAS G12C–Mutated Advanced mCRC
Tissue-Based NGS May Help Determine Relevant Gene Copy Number Gain Cutpoint for HER2/KRAS/MET in NSCLC
Routine Intraoperative Frozen Section Represents a "Very Costly" Soft Tissue Sarcoma Procedure
OS With Chemotherapy Is Linked With Baseline Geriatric, QOL Factors in Metastatic Pancreatic Cancer
Watson Unpacks the Potential Clinical Impact of High-Level MET, HER2, and KRAS Amplifications in NSCLC
2 Commerce Drive
Cranbury, NJ 08512